Richard Thomas Williams's Insider Trades & SAST Disclosures
Richard Thomas Williams's most recent trade in Kinnate Biopharma Inc was a trade of 558 Common Stock done at an average price of $2.6 . Disclosure was reported to the exchange on March 1, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Richard Thomas Williams.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kinnate Biopharma Inc | Richard Thomas Williams | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.59 per share. | 01 Mar 2024 | 558 | 67,588 | - | 2.6 | 1,445 | Common Stock |
| Kinnate Biopharma Inc | Thomas Williams Richard | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.25 per share. | 01 Dec 2023 | 541 | 68,146 | - | 2.2 | 1,217 | Common Stock |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.30 per share. | 01 Jun 2023 | 541 | 69,228 | - | 4.3 | 2,326 | Common Stock |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.21 per share. | 01 Mar 2023 | 638 | 67,295 | - | 5.2 | 3,324 | Common Stock |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 215,000 | 215,000 | - | - | Employee Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.75 per share. | 01 Dec 2022 | 541 | 67,933 | - | 7.8 | 4,193 | Common Stock |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 25,000 | 68,474 | - | 0 | Common Stock | |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 8.37 per share. | 11 Mar 2022 | 25,000 | 42,333 | - | 8.4 | 209,250 | Common Stock |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 8.64 per share. | 11 Mar 2022 | 15,000 | 17,333 | - | 8.6 | 129,600 | Common Stock |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Kinnate Biopharma Inc | Richard Thomas Williams | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2021 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges